RenovoRx (RNXT) announced the appointment of interventional oncologist Thierry de Baere, MD, PhD to RenovoRx’s Scientific Advisory Board, SAB. Professor de Baere’s expertise is directly relevant to RenovoRx’s Trans-Arterial Micro-Perfusion therapy platform which is enabled by RenovoCath. This patented technology is designed to optimize targeted drug-delivery of therapeutic agents.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx announces first patient procedure completed in PanTheR study
- RenovoRx’s Earnings Call: Positive Outlook Amid Growth
- Buy Rating Affirmed for RenovoRx Amid Promising Phase 3 Study Progress and Potential Stock Catalyst
- RenovoRx’s Promising Product Launch and Strategic Expansion Drive Buy Rating
- RenovoRx’s PanTheR Registry Trial: A Promising Update for Investors